CHAPTER 2 Preparation for endoscopy
2.1 Management of patients on antithrombotic therapy prior to gastrointestinal endoscopy
Key Points
1 Procedure-related bleeding
Procedure risk may be classified as below.
1.2 High-risk procedures
1.2.1 High risk of bleeding
Table 1 summarizes the estimated risks of bleeding with various endoscopic procedures (1% or more), in settings where the bleeding can be managed endoscopically.
Procedure | Estimated bleeding risk (%) |
---|---|
Colonic polypectomy | 1–2.5 |
Gastric polypectomy or jumbo/snare biopsy | 4 |
Endoscopic mucosal resection | ≤22 |
Ampullectomy | 8 |
Endoscopic sphincterotomy | 2.5–5 |
Photodynamic therapy | ≤6 |
Endoscopic treatment of esophageal or gastric varices | ≤6 |
Endoscopic hemostasis of vascular lesions | ≤5 |
2 Bleeding associated with antithrombotic therapy
2.1 Antiplatelet drugs
These drugs inhibit platelet function, particularly activation and aggregation.
3 Risks associated with discontinuation of antithrombotic therapy
3.1 Patients receiving oral anticoagulants
3.1.1 Indications associated with acute thromboembolic risk (Table 2)
When taking a patient off warfarin, it is essential to use a specific protocol (Box 2) involving unfractionated heparin. It is also advisable to carefully weigh whether the planned procedure is truly indicated, and if so, undertake procedures associated with a low risk of bleeding (e.g. insertion of a biliary stent without sphincterotomy).
Condition | Target INR |
---|---|
All prosthetic metal valves in a mitral position | 3–4.5 |
All first-generation metal aortic valves | 3–4.5 |
Second-generation aortic valves in patients with an additional embolic risk factor | 3–4.5 |
Atrial fibrillation associated with other thromboembolic risk factors, particularly mitral valve disease | 2–3 |
Box 2 Patients receiving warfarin
Switching medications in patients with acute thromboembolic risk
3.1.2 Indications associated with low or moderate thromboembolic risk (Box 3)
Box 3 Indications associated with low or moderate thromboembolic risk
Temporary discontinuation of antithrombotic therapy is usually sufficient in these situations.
3.2 Patients receiving antiplatelet drugs
3.2.1 Indications associated with acute thromboembolic risk (Box 4)
Box 4 Patients receiving antiplatelet drugs
Switching medications in patients with acute thromboembolic risk
4 Switching from warfarin or antiplatelet drugs to alternative therapy
No drug has been approved for switching from warfarin or antiplatelet therapy. The discontinuation/switching procedure takes account of the treatment currently being used and the patient’s thromboembolic risk factors (Boxes 2 and 4).
LMWHs are an alternative and are administered using the same protocol as for switching to warfarin.
6 Recommendations
6.2 Setting-specific therapy adjustments
6.2.1 High-risk procedures
Elevated risk of bleeding (1% or more), if the patient can be treated endoscopically (Table 3):
Low risk of bleeding (<1%) in patients who cannot be monitored endoscopically:
6.3 Treatment discontinuation and resumption
Conclusion
It is difficult to formulate recommendations that will cover all possible clinical scenarios that endoscopists will encounter. The bleeding risk associated with the procedure and the underlying pathology (thromboembolic risk) must be assessed on a case-by-case basis. Clear communication between the endoscopist and the prescribing physician is important in deciding the best strategy. The guidance provided in this chapter can potentially serve as a basis for such discussions but it should be borne in mind that this consensus is somewhat arbitrary in places because of lack of an evidence base for recommendations and also because guidelines differ from country to country. The British Society of Gastroenterology guidelines, for example, include a simple, practical flowchart that is a useful starting point for many of the common clinical situations (Fig. 1).
American Society of Gastrointestinal Endoscopy. Management of antithrombotic agents for endoscopic procedures. Gastrointest Endosc. 2009;70:1060-1070.
Boustière C, Veitch A, Vanbiervliet, et al. Endoscopy and antiplatelet agents. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2011;43(5):445-461.
Hui AJ, Wong RM, Ching JY, et al. Risk of colonoscopy polypectomy bleeding with anticoagulants and antiplatelet agents: analysis of 1657 cases. Gastrointest Endosc. 2004;59:44-48.
Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: the relationships among dose, effectiveness, and optimal therapeutic range. Chest. 2001;119(1 Suppl):39S-63S.
Samama CM, Djoudi R, Lecompte T, et alAFSSAPS Expert Group. Perioperative platelet transfusion: recommendations of the Agence française de sécurité sanitaire des produits de santé (AFSSAPS)] 2003. and the. Can J Anesth. 2005;52:30-37.
Stein PD, Alpert JS, Bussey HI, et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest. 2001;119(1 Suppl):220S-227S.
Veitch AM, Baglin TP, Gershlick SH, et al. Guidelines for the management of anticoagulant and antiplatelet therapy in patients undergoing endoscopic procedures. Gut. 2008;57:1322-1329.
Yousfi M, Gostout CJ, Baron TH, et al. Postpolypectomy lower gastrointestinal bleeding: potential role of aspirin. Am J Gastroenterol. 2004;99(9):1785-1789.
Zuckerman MJ, Hirota WK, Adler DG, et al. ASGE guideline: the management of low-molecular-weight heparin and nonaspirin antiplatelet agents for endoscopic procedures. Gastrointest Endosc. 2005;61:189-194.
2.2 Antibiotic prophylaxis
Key Points
Introduction
European and American Society guidelines (Table 1) have recently changed significantly with respect to antibiotic prophylaxis against infective endocarditis. Antibiotics are no longer recommended for gastrointestinal procedures in the absence of established infection, but are still recommended for patients with evidence of infection prior to endoscopy and in patients undergoing specific procedures, which are discussed below.
Society | Recommendation | Further Reading |
---|---|---|
AHA 2007 | Prophylaxis against infective endocarditis is not recommended for non-dental procedures such as transesophageal echocardiogram, EGD or colonoscopy in the absence of active infection. | Wilson et al 2007; Nishimura et al 2008 |
NICE 2008 | Antibiotic prophylaxis for gastrointestinal procedures is not recommended. | Richey et al 2008 |
ESC | Antibiotic prophylaxis is not recommended for gastroscopy, colonoscopy, or transesophageal echocardiography. | Habib et al 2009 |
BSG | Antibiotics are not indicated as prophylaxis against infective endocarditis. | Allison et al 2009 |
ASGE | Antibiotic prophylaxis for infectious endocarditis is not recommended. | Banerjee et al 2008 |
AHA, American Heart Association; NICE, National Institute for Heath and Clinical Excellence; ESC, European Society of Cardiology; BSG, British Society of Gastroenterology; ASGE, American Society of Gastrointestinal Endoscopy.
1 Antibiotics for the prevention of infective endocarditis
European and American societies have recently significantly altered their recommendations for endocarditis prophylaxis in patients undergoing endoscopy (see Further Reading). The rationale for these changes has been summarized by the European Society of Cardiology:
2 Antibiotic prophylaxis in specific groups of patients
The guidelines of the American Society of Gastrointestinal Endoscopy can be found in Table 2.
2.2 Vascular grafts or prostheses
Antibiotic prophylaxis is not recommended for patients with vascular grafts or prostheses.
3 Antibiotic prophylaxis for specific endoscopic procedures
See Table 3 for recommended antibiotics based on the British Society of Gastroenterology guidelines.
Procedure | Antibiotic coverage |
---|---|
ERCP | Ciprofloxacin 750 mg PO 90 min pre-procedure |
or | |
Gentamicin 1.5 mg/kg IV | |
OLT undergoing ERCP | Ciprofloxacin 750 mg 90 min pre-procedure |
or | |
Gentamicin 1.5 mg/kg IV | |
PLUS | |
Amoxicillin 1 g IV or vancomycin 20 mg/kg IV infused over at least one hour | |
EUS FNA cystic lesion | Co-amoxiclav 1.2 g IV |
or | |
Ciprofloxacin 750 mg PO 90 min pre-procedure | |
3–5 day course of antibiotics post-procedure is usually given | |
Antibiotics should be given prior to performing EUS-FNA | |
PEG | Co-amoxiclav 1.2 g IV |
or | |
Second or third generation cephalosporin (i.e. cefuroxime 750 mg IV) | |
Teicoplanin 400 mg IV can be used in patients who are penicillin allergic | |
Antibiotics should be given prior to commencing the procedure | |
Cirrhosis with upper-GI bleed | Piperacillin/tazobactam 4.5 g IV three times per day |
or | |
Third generation cephalosporin (i.e. cefotaxime 2 g IV three times per day) |
PEG, percutaneous endoscopic gastrostomy; ERCP, endoscopic retrograde cholangiopancreatogram; OLT, orthotopic liver transplant; EUS, endoscopic ultrasound; FNA, fine needle aspiration biopsy.
a Based on British Society of Gastroenterology guidelines. Oral antibiotics should be given 60–90 min pre-procedure to allow absorption of the drug.
3.1 ERCP
Recommendations for patients undergoing ERCP:
Allison MC, Sandoe JA, Tighe R, et al. Antibiotic prophylaxis in gastrointestinal endoscopy. Gut. 2009;58:869-880.
(Guidelines of the British Society of Gastroenterology)
Banerjee S, Shen B, Baron TH, et al. Antibiotic prophylaxis for GI endoscopy. Gastrointest Endosc. 2008;67:791-798.
(Guidelines of the American Society of Gastrointestinal Endoscopy)
Danchin N, Duval X, Leport C. Prophylaxis of infective endocarditis: French recommendation v2002. Heart. 2005;91:715-718.
Habib G, Hoen B, Tornos P, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis. The task force on the prevention, diagnosis, and the treatment of infective endocarditis of the European Society of Cardiology. Eur Heart J. 2009;30:2369-2413.
Nishimura RA, Carabello BA, Faxon DP, et al. ACC/AHA 2008 Guideline update on valvular heart disease: focused update on infective endocarditis. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2008;118:887-896.
(Guidelines from the American College of Cardiology and American Heart Association)
Richey R, Wray D, Stokes T. Prophylaxis against infective endocarditis: summary of NICE guidance. BMJ. 2008;336:770-771.
Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis. Guidelines from the American Heart Association. Circulation. 2007;116:1736-1754.